University of Patras
Η επίδραση της παρστατίνης 1-26 στη μυοκαρδιακή βλάβη από ισχαιμία και επαναιμάτωση: μελέτη σε πειραματικό μοντέλο κονίκλων
Abstract
dc:descriptionExenatide and ciclosporin have been shown to partially protect myocardial tissue damage after reperfusion. In the present thesis it is proposed to combine more than one cardioprotective agent, targeting more pharmacological targets, where it could provide more effective myocardial protection and achieve a more improved outcome in these patients. In addition to this study, we used a model of reperfusion injury in rabbits and showed that monotherapy with either exenatide or ciclosporin or paratain 1-26 resulted in a reduction in myocardial tissue damage to a similar extent. This indicates that each agent alone has limited and finite cardioprotective ability. However, when the combination of exenatide and cyclosporine was used, we managed to have a more enhanced (additive) reduction in tissue damage. Exenatide has been found in a wide range of studies to have effective action, including clinical studies without pharmacological side effects. This makes it an ideal candidate for combination therapy. As far as we know, there are no other previous studies to analyze the combination of exenatide agents to increase cardioprotection by acute coronary occlusion. Similarly, there are no previous studies to investigate the effect of ciclosporin in combination with other pharmaceutical agents. In fact, few studies with combination therapy for reperfusion injury are associated with a combination of pharmaceutical agents and mechanical interventions. In the present study rabbits were subjected to 40 minutes of ischemia and 120 minutes of reperfusion. Intravenous administration of exenatide or cyclosporine A was done 10 minutes prior to reperfusion. The reduction in myocardial tissue damage was 38% (P <0.05) and 40% (P <0.05), respectively. While levels of cardiac troponin I (cTnI) in plasma decreased by 48% (P <0.05) and 36% (P <0.05), respectively, compared to the control group. The combined administration of both agents resulted in an additional reduction in infarct size of 55% (P <0.05) and in the release of cTnI by 61% (P <0.05). Also, combined exenatide and paratain 1-26 therapy increased the reduction in infarct size by 62% (P <0.05), compared with monotherapy 41% for paratain 1-26 (P <0.05) , 43% for exenatide (P <0.05). In contrast, the combined administration of parasite 1-26 and ciclosporin cancels the cardioprotective effects seen in monotherapy. These results indicate that for the treatment of injured myocardium by reperfusion, the combined administration of exenatide and cyclosporin A or parstatin 1-26 is more effective than monotherapies and may offer a more advantageous clinical effect.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Alexopoulos, Panagiotis
- Αλεξόπουλος, Παναγιώτης
Subjects
dc:subject × 17- Παρστατίνη 1-26
- Βλάβες ισχαιμίας / επαναιματώσεως
- 'Έμφραγμα μυοκαρδίου
- Κυκλοσπορίνη Α
- Εξενατίδη
- Πειραματικό μοντέλο
- Κόνικλοι
- Parstatin 1-26
- Ischemia reperfusion injury
- Acute myocardial infarction
- Cyclosporine A (C2A)
- Exenatide
- Experimental model of rabbits
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43436